Invest in the Future of Brain Injury Detection
At ArcheOptix, we’re changing how the world detects and responds to traumatic brain injuries. Our proprietary, non-invasive brain scanning technology offers CT-level sensitivity and specificity, accurately identifying 95-98% of acute subdural and epidural hematomas within minutes.
Every year, millions of people suffer head injuries, and yet, 90-93% of CT scans ordered for these patients show no bleeding. ArcheOptix's NIRD® technology bridges that diagnostic gap, saving time, reducing unnecessary hospital transfers, and improving patient outcomes.
With the growing demand for point-of-care diagnostics across emergency response, rural health, sports medicine, military, and hospital settings, the market is ready. And, we’re positioned to lead it.
Our Technology at a Glance
The Opportunity
We’re actively seeking investment to scale our manufacturing, accelerate regulatory approvals in new markets, expand our R&D capabilities, and deepen our partnerships across multiple industries.
Your investment will help us:
- Increase production to meet rising demand.
- Expand global reach with strategic partnerships.
- Innovate further with AI-enhanced diagnostics.
- Grow our team and infrastructure.